The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Patient-reported outcomes with the use of elranatamab in the MagnetisMM-3 trial
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares some insights into patient-reported outcomes (PROs) with the use of elranatamab in relapsed/refractory (R/R) multiple myeloma in patients enrolled in the MagnetisMM-3 trial (NCT04649359). Prof. Mohty further emphasizes the importance of including PRO measurements in clinical trials. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
